-
Je něco špatně v tomto záznamu ?
Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation
J. Aaseth, J. Alexander, G. Bjørklund, K. Hestad, P. Dusek, PM. Roos, U. Alehagen,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
NLK
ProQuest Central
od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-03-01 do Před 1 rokem
- MeSH
- Alzheimerova nemoc dietoterapie farmakoterapie metabolismus MeSH
- lidé MeSH
- oxidační stres účinky léků MeSH
- potravní doplňky * MeSH
- sloučeniny selenu aplikace a dávkování metabolismus farmakologie terapeutické užití MeSH
- zánět farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Alzheimer's disease (AD) is a neurodegenerative disorder presenting one of the biggest healthcare challenges in developed countries. No effective treatment exists. In recent years the main focus of AD research has been on the amyloid hypothesis, which postulates that extracellular precipitates of beta amyloid (Aβ) derived from amyloid precursor protein (APP) are responsible for the cognitive impairment seen in AD. Treatment strategies have been to reduce Aβ production through inhibition of enzymes responsible for its formation, or to promote resolution of existing cerebral Aβ plaques. However, these approaches have failed to demonstrate significant cognitive improvements. Intracellular rather than extracellular events may be fundamental in AD pathogenesis. Selenate is a potent inhibitor of tau hyperphosphorylation, a critical step in the formation of neurofibrillary tangles. Some selenium (Se) compounds e.g. selenoprotein P also appear to protect APP against excessive copper and iron deposition. Selenoproteins show anti-inflammatory properties, and protect microtubules in the neuronal cytoskeleton. Optimal function of these selenoenzymes requires higher Se intake than what is common in Europe and also higher intake than traditionally recommended. Supplementary treatment with N-acetylcysteine increases levels of the antioxidative cofactor glutathione and can mediate adjuvant protection. The present review discusses the role of Se in AD treatment and suggests strategies for AD prevention by optimizing selenium intake, in accordance with the metal dysregulation hypothesis. This includes in particular secondary prevention by selenium supplementation to elderly with mild cognitive impairment.
Council for Nutritional and Environmental Medicine Mo i Rana Norway
Norwegian Institute of Public Health Oslo Norway Norwegian University of Life Sciences Ås Norway
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18011062
- 003
- CZ-PrNML
- 005
- 20180419094525.0
- 007
- ta
- 008
- 180404s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10534-016-9959-8 $2 doi
- 035 __
- $a (PubMed)27530256
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Aaseth, Jan $u Department of Research, Innlandet Hospital Trust, Brumunddal, Norway. Department of Public Health, Hedmark University of Applied Sciences, Elverum, Norway.
- 245 10
- $a Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation / $c J. Aaseth, J. Alexander, G. Bjørklund, K. Hestad, P. Dusek, PM. Roos, U. Alehagen,
- 520 9_
- $a Alzheimer's disease (AD) is a neurodegenerative disorder presenting one of the biggest healthcare challenges in developed countries. No effective treatment exists. In recent years the main focus of AD research has been on the amyloid hypothesis, which postulates that extracellular precipitates of beta amyloid (Aβ) derived from amyloid precursor protein (APP) are responsible for the cognitive impairment seen in AD. Treatment strategies have been to reduce Aβ production through inhibition of enzymes responsible for its formation, or to promote resolution of existing cerebral Aβ plaques. However, these approaches have failed to demonstrate significant cognitive improvements. Intracellular rather than extracellular events may be fundamental in AD pathogenesis. Selenate is a potent inhibitor of tau hyperphosphorylation, a critical step in the formation of neurofibrillary tangles. Some selenium (Se) compounds e.g. selenoprotein P also appear to protect APP against excessive copper and iron deposition. Selenoproteins show anti-inflammatory properties, and protect microtubules in the neuronal cytoskeleton. Optimal function of these selenoenzymes requires higher Se intake than what is common in Europe and also higher intake than traditionally recommended. Supplementary treatment with N-acetylcysteine increases levels of the antioxidative cofactor glutathione and can mediate adjuvant protection. The present review discusses the role of Se in AD treatment and suggests strategies for AD prevention by optimizing selenium intake, in accordance with the metal dysregulation hypothesis. This includes in particular secondary prevention by selenium supplementation to elderly with mild cognitive impairment.
- 650 _2
- $a Alzheimerova nemoc $x dietoterapie $x farmakoterapie $x metabolismus $7 D000544
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a potravní doplňky $7 D019587
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x farmakoterapie $7 D007249
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a sloučeniny selenu $x aplikace a dávkování $x metabolismus $x farmakologie $x terapeutické užití $7 D018036
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Alexander, Jan $u Norwegian Institute of Public Health, Oslo, Norway. Norwegian University of Life Sciences (NMBU), Ås, Norway.
- 700 1_
- $a Bjørklund, Geir $u Council for Nutritional and Environmental Medicine, Mo i Rana, Norway.
- 700 1_
- $a Hestad, Knut $u Department of Research, Innlandet Hospital Trust, Brumunddal, Norway. Department of Public Health, Hedmark University of Applied Sciences, Elverum, Norway.
- 700 1_
- $a Dusek, Petr $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Roos, Per M $u Institute of Environmental Medicine, IMM, Karolinska Institutet, Nobels väg 13, Box 210, 17177, Stockholm, Sweden. per.roos@ki.se. Department of Clinical Physiology, St.Goran Hospital, Stockholm, Sweden. per.roos@ki.se.
- 700 1_
- $a Alehagen, Urban $u Division of Cardiovascular Medicine, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
- 773 0_
- $w MED00007558 $t Biometals an international journal on the role of metal ions in biology, biochemistry, and medicine $x 1572-8773 $g Roč. 29, č. 5 (2016), s. 827-39
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27530256 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180419094626 $b ABA008
- 999 __
- $a ok $b bmc $g 1288547 $s 1007874
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 29 $c 5 $d 827-39 $e 20160816 $i 1572-8773 $m BioMetals $n Biometals $x MED00007558
- LZP __
- $a Pubmed-20180404